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Abstract: Due to the binding to a number of proteins to the receptor protomers in receptor heteromers
in the brain, the term “heteroreceptor complexes” was introduced. A number of serotonin 5-HT1A
heteroreceptor complexes were recently found to be linked to the ascending 5-HT pathways known
to have a significant role in depression. The 5-HT1A–FGFR1 heteroreceptor complexes were involved
in synergistically enhancing neuroplasticity in the hippocampus and in the dorsal raphe 5-HT nerve
cells. The 5-HT1A protomer significantly increased FGFR1 protomer signaling in wild-type rats.
Disturbances in the 5-HT1A–FGFR1 heteroreceptor complexes in the raphe-hippocampal 5-HT system
were found in a genetic rat model of depression (Flinders sensitive line (FSL) rats). Deficits in FSL
rats were observed in the ability of combined FGFR1 and 5-HT1A agonist cotreatment to produce
antidepressant-like effects. It may in part reflect a failure of FGFR1 treatment to uncouple the 5-HT1A
postjunctional receptors and autoreceptors from the hippocampal and dorsal raphe GIRK channels,
respectively. This may result in maintained inhibition of hippocampal pyramidal nerve cell and
dorsal raphe 5-HT nerve cell firing. Also, 5-HT1A–5-HT2A isoreceptor complexes were recently
demonstrated to exist in the hippocampus and limbic cortex. They may play a role in depression
through an ability of 5-HT2A protomer signaling to inhibit the 5-HT1A protomer recognition and
signaling. Finally, galanin (1–15) was reported to enhance the antidepressant effects of fluoxetine
through the putative formation of GalR1–GalR2–5-HT1A heteroreceptor complexes. Taken together,
these novel 5-HT1A receptor complexes offer new targets for treatment of depression.
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1. Introduction
In membrane preparations of various central nervous system (CNS) regions, it was found in the
1980s that neuropeptides such as CCK8 and neurotensin could modulate the binding characteristics
via their receptors, especially the affinity of the monoamine receptors in a receptor subtype-specific
way [1–3]. In 1993, the concept was introduced that such receptor–receptor interactions took place in
heterodimers [4]. In 2010, the role of higher-order heteromers was also underlined as being centers of
integration, as demonstrated in cellular models [5]. In tissues, it is better to speak of heteroreceptor
complexes, because little is known of their composition and stoichiometry and of the participation
of adaptor proteins [6,7]. Thus, a number of proteins can bind to the receptor protomers, such as
GPCR-interacting proteins (adaptor proteins), which can vary from one brain region to another as
well as the stoichiometry of the participating receptors. Also, other receptors can be added to the
heteroreceptor complexes in a dynamic way [8]. Furthermore, ion channels and transmitter transporters
can also participate in such heteroreceptor complexes, increasing their signaling panorama. As a result
of such changes, their allosteric receptor–receptor interactions can become altered. The allosteric
receptor–receptor interactions in heteroreceptor complexes give diversity and bias to the receptor
protomers due to conformational changes in discrete receptor domains altering receptor protomer
function and pharmacology [8,9].
Another term used is “isoreceptor complex”. In contrast to the heteroreceptor complex,
the different receptors in the isoreceptor complex always bind the same transmitter, for example,
serotonin (5-HT). Thus, the 5-HT1A–5-HT2A receptor complex represents an isoreceptor complex,
while the 5-HT1A–FGFR1 receptor complex represents a heteroreceptor complex.
The overall architecture of the global GPCR heterodimer network [10] shows a scale-free topology,
because most protomers participate only in a couple of interactions. However, a few have more than
ten connections (heterodimerization) to other GPCR protomers such as D2R and 5-HT1A receptors,
in addition to direct interactions with receptor tyrosine kinase (RTK) [6,11–16] and ligand-gated ion
channel receptors [17–19].
Serotonin receptor mechanisms play a major role in the development of depression and its
treatment [20]. In 1967, the 5-HT uptake mechanism was found in the plasma membrane at the soma,
axon, and terminal level of the central 5-HT neurons [21]. In 1968, Carlsson et al. reported that
imipramine can block the 5-HT uptake mechanism, which led to the search for selective serotonin
reuptake inhibitors (SSRIs) in the treatment of depression [22]. Postjunctional 5-HT1A receptors are
today currently in the center of interest among the many 5-HT isoreceptors identified and regarded to
be involved in the antidepressant actions of SSRIs [23–26].
Basic neurobiological research as well as clinical studies on SSRIs have established that
disturbances in the ascending 5-HT neuron systems and their collateral networks to the forebrain, as
well as their many 5-HT receptor subtypes, contribute to the etiology of depression and are targets
for its treatment [14,23,26–31]. The therapeutic action of serotonin antidepressant drugs is of proven
effectiveness, but the mechanisms underlying their effect are still unclear. There are many 5-HT
receptor subtypes involved and some need to be blocked (e.g., 5-HT2AR, 5-HT3R, and 5-HT7R),
while others need to be activated (e.g., postjunctional 5-HT1AR and 5-HT4R) [14,29]. Therefore,
5-HT subtype-selective antagonists or agonists can be used, inter alia, to enhance the antidepressant
actions of SSRIs [29,32]. These state-of-the-art developments are in line with the hypothesis that the
development of depression can involve an imbalance of the activity between different types of 5-HT
isoreceptors [33,34]. Multi-targeting drugs, such as vortioxetine, with serotonin transporter-blocking
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properties together with a high affinity for a number of 5-HT isoreceptors are currently being tested
for their potential to treat depressive disorders [26,35]. However, the 5-HT1AR remains in the center
of interest [26,35,36].
It is known from our work that 5-HT1AR forms heteromers with many other receptors in neuronal
membranes of the brain linked to the ascending 5-HT neurons [6,11,13,34,37–44]. They are of relevance
for depression and its treatment. In this focused review, we will present an update of the work
on the brain 5-HT1A–FGFR1 heteroreceptor complexes [6,11,13,14,39,40] and the demonstration
of a novel 5-HT1A receptor complex: the brain 5-HT1A–5-HT2A isoreceptor complex [34]. The
complex yet exciting world of brain GalR–5-HT1A heteroreceptor complexes will also be briefly
discussed [37,42,43,45] (Figure 1).
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Figure 1. Illustration of how serotonin volume transmission can reach the 5-HT1A–FGFR1,
5-HT1A–5-HT2A, GalR1–5-HT1A, and GalR1–GalR2–5-HT1A heteroreceptor complexes. The ligand
for the GalR1–GalR2 heterodimer is the galanin fragment Gal (1–15), while galanin (1–19) is the ligand
for galanin receptor monomers and homomers. The 5-HT1A heteroreceptor complexes may mainly
have an extrasynaptic location, but also a synaptic location. They are proposed to modulate synaptic
glutamate transmission in pyramidal neurons of the hippocampus and synaptic GABA transmission in
inhibitory GABA interneurons of the hippocampus. The differential role of these hippocampal 5-HT1A
heteroreceptor complexes in modulating the hippocampal networks remain to be characterized.
2. FGFR1–5-HT1A Heteroreceptor Complexes
These complexes have been observed in the hippocampus and in the dorsal raphe 5-HT
neurons [6,13,40,46] using the in situ proximity ligation assay (in situ PLA) [46–48] (Figure 1).
In the dorsal raphe, the 5-HT1A receptor functions as an autoreceptor [25,29,49,50]. Acute and
repeated combined intracerebroventricular (i.c.v.) treatment with basic fibroblast growth factor
(FGF2) and the 5-HT1AR agonist 8-OH-DPAT produced evidence of robust and highly significant
antidepressant-like actions in the FST [6,13] due to synergistic allosteric receptor–receptor interactions.
Increased recruitment of β-arrestin2 t the 5-HT1A protomer was observed together with an increased
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participation of 5-HT1A homodimers in the heteroreceptor complex upon combined FGF2 and
5-HT1AR agonist treatment [15,39].
2.1. Neurophysiological Studies
In a recent paper [11], it was found in control Sprague Dawley rats that FGF2 and a FGFR1
receptor agonist Sun-11602 diminished the currents over the G protein-coupled inwardly rectifying
potassium channels (GIRK) produced by a 5-HT1A receptor agonist in pyramidal nerve cells of the
CA1 region (Ammon's horn). An allosteric antagonistic receptor–receptor interaction may mediate
these effects in the 5-HT1A–FGFR1 heteroreceptor complex. Previously, 5-HT1AR was shown to be
located at the soma-dendritic level of the hippocampal pyramidal neurons [51]. Similar events may
also take place in the 5-HT1A autoreceptor, known to be coupled to GIRK channels, and be part
of the F5-HT1A–FGFR1 heteroreceptor complexes in the dorsal raphe [13,40,52,53]. However, such
interactions remain to be analyzed.
2.2. Acute i.c.v. Effects of FGF2 and a 5-HT1A Agonist in a Genetic Rat Model of Depression Compared with
Control Sprague Dawley (SD) Rats
2.2.1. Behavioral Analysis
The Flinders sensitive line (FSL) rats were chosen, with the SD rat as a control. The FSL rats
demonstrate a number of depression-like symptoms, for example, behavioral distress and deficiency in
learning and memory [54]. I.c.v. injections of FGF2 and/or 8-OH-DPAT in the FSL and control strains
were made and their acute effects over 48 hours evaluated in the forced swim test. The SD rats, as
observed previously [6], demonstrated a reduction of the immobility time upon combined treatment
with FGF2 and 8-OH-DPAT, not observed with single treatment. Such synergistic interactions were not
observed in the genetic rat model of depression, which is of high interest [11]. Instead, in FSL rats,
a reduction of immobility time was found after treatment with the 5-HT1A agonist treatment alone,
which was blocked by combined treatment with FGF2. A neurophysiological correlation to these
differential changes obtained in the FSL rats has not yet been obtained. However, a link to alterations
in the 5-HT1A–FGFR1 heteroreceptor complexes does exist.
2.2.2. In Situ PLA Analysis
In the control rats, it was of substantial interest to find that the combined, but not single treatment,
selectively increased the number of 5-HT1A–FGFR1 heteroreceptor complexes in the CA2 area, but not
in CA1 and CA3 areas [11]. The CA2 pyramidal cells have special features with projections especially
to the deep layer of the CA1 pyramidal cells [55]. Furthermore, the CA2 projections strongly control
the ventral CA1 efferents to the prefrontal cortex and the basolateral amygdala [56]. In addition, the
CA2 projections appear to have a key role in social memory [57], which is in line with the current
observations that the CA2 projections may have a role in depression.
Moving to 5-HT1A–FGFR1 heteroreceptor complexes of the FSL rats, single treatment with the
5-HT1A receptor agonist alone, but not combined treatment, significantly increased the number of
5-HT1A–FGFR1 heteroreceptor complexes in the CA2 and CA3 areas of the dorsal hippocampus [11].
These results match the behavioral data and indicate that 5-HT1A agonist treatment alone, by increasing
the hippocampal 5-HT1A–FGFR1 heteroreceptor complexes in the CA2 and CA3 regions, can contribute
to the antidepressant-like effects observed with 8-OH-DPAT alone. It may be proposed that the
differential effects observed in control versus FSL rats can be related to differential composition and
stoichiometry of the 5-HTR1A–FGFR1 receptor complexes in the control rats compared with the
depressed FSL rats. The allosteric receptor–receptor interactions may therefore change, and a different
pharmacology can then also develop.
Significant increases in the 5-HT1A–FGFR1 autoreceptor complexes were observed in the dorsal
raphe after treatment with the 5-HT1A agonist in the absence or presence of FGF2 cotreatment in
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the control rat [11]. However, antidepressant-like effects were only noticed after combined i.c.v.
treatment. It may therefore be that FGF2 treatment is necessary for the reduced coupling of the
5-HT autoreceptor to the GIRK channel in this autoreceptor complex. This will lead to reduced
hyperpolarization and increased firing of the ascending 5-HT pathways originating from this nucleus
and thus to antidepressant activity [58–60].
It should be noticed that in the FSL rats, no changes in the density of 5-HT1A–FGFR1 autoreceptor
complexes were observed in the dorsal raphe of the FSL rat after 5-HT1A receptor agonist and/or
FGF2 treatment. The reason for this is unclear, however, because there was an indication for a possible
increase of the 5-HT1A–FGFR1 autoreceptor complexes in the dorsal raphe versus the control rat.
Such an increase may counteract an additional increase in these 5-HT1A autoreceptor complexes upon
treatment with 5-HT1A agonist and/or FGF2. Further studies are therefore necessary in combination
with a neurophysiological analysis to evaluate if a compensatory reduction of 5-HT1A autoreceptor
coupling to GIRK channels has developed in the FSL rats in the dorsal raphe to increase firing in the
ascending 5-HT pathways.
The antidepressant-like effect found in the FSL rats after i.c.v. treatment with 5-HT1A receptor
agonist alone may be produced by the ability of this treatment to increase the 5-HT1A–FGFR1
heteroreceptor complexes in the CA2–CA3 areas of the dorsal hippocampus [11]. In contrast, in control
rats, only combined treatment produced increases in these heteroreceptor complexes and only in
the CA2 areas of the dorsal hippocampus. It seems possible that the allosteric receptor–receptor
interactions in these receptor complexes differ between treatments due to their differences in
composition and stoichiometry in the two rat strains. As a result, the densities may vary with
the pharmacological treatment as well as the allosteric modulation of the 5-HT1A coupling to the GIRK
channels, with alterations in the firing of the pyramidal nerve cells of the CA2 and CA3 areas.
3. 5-HT1A–5-HT2A Isoreceptor Complexes
There exist 5-HT1A–5-HT7 isoreceptor complexes, as demonstrated in cellular models [61]. They
appear to be in equilibrium with 5-HT1A and 5-HT7 homodimers and with monomers. The allosteric
receptor–receptor interaction is characterized by the ability of 5-HT7 to inhibit the Gi/o-mediated
5-HT1A signaling, leading to a reduction of the ability of 5-HT1A receptors to open the GIRK
channels [61].
According to the triplet puzzle theory [62], triplet amino acid homologies participate in the
receptor interface and guide the two receptors towards each other. This was true also for the
5-HT1A–5-HT2A isoreceptor complex [34], in view of the fact that 5-HT1A and 5-HT2A receptors also
possessed two triplet amino acid homologies in a putative interface. The existence of a 5-HT1A–5-HT2A
isoreceptor complex was therefore postulated [34] (Figure 1).
Evidence for its existence was obtained using BRET (Bioluminescence Resonance Energy Transfer
Method) and in situ proximity ligation assay (in situ PLA) in cellular models. The existence of the
5-HT1A–5-HT2A isoreceptor complex in the brain was also found with in situ PLA. The complex was
present in the pyramidal cell layer of the CA1–CA3 areas and in the anterior cingulate cortex [34].
The complexes in the hippocampal regions were studied 24 hours following the forced swim test
and found to be vulnerable to the stress, shown by their marked reduction in the CA1–CA2 areas.
As to the allosteric receptor–receptor interactions, antagonistic 5-HT2A–5-HT1A interactions were
demonstrated both in the hippocampus and in the frontal lobe.
A standard 5-HT2A agonist reduced the affinity of the 5-HT1A agonist binding sites in the
two regions. Postjunctional 5-HT1A receptors in the forebrain are regarded as partly mediating
antidepressant effects of selective serotonin reuptake inhibitors [23,26]. Therefore, a dominance of
5-HT2A receptor protomer activity may contribute to depressive effects in mood disorder through this
mechanism. In line with these results, it was indicated early on that classical antidepressant drugs
may block 5-HT2A receptors [63,64]. Depressed patients show a higher density of 5-HT2A receptors
than normal patients, indicating a role of 5-HT2A receptors in depression development [65]. Thus,
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these two major 5-HT receptor subtypes interact in heteroreceptor complexes in limbic regions, which
can contribute to their role in depression.
4. Multiple GalR–5-HT1A Heteroreceptor Complexes: Focus on GalR1–GalR2 Heterodimer and
GalR1–GalR2–5-HT1A Heteroreceptor Complexes
4.1. Galanin N-Terminal Fragment (Gal (1–15))
The receptor for the galanin N-terminal fragment (Gal (1–15)) is the GalR1–GalR2 isoreceptor
dimer [38,66,67], for which Gal (1–15) has a high affinity. It is of high interest that Gal (1–15) peptide
given alone exerts strong depression-related and anxiogenic-like effects by targeting GalR1–GalR2
heterocomplexes in the raphe-limbic 5-HT system [67]. In contrast, Gal (1–15) enhances the
antidepressant actions of the 5-HT1A receptor agonist 8-OH-DPAT [42]. The putative existence of a
trimeric GalR1–GalR2–5-HT1A heteroreceptor complex was therefore postulated. The existence of the
trimeric receptor complex may lead to novel allosteric receptor–receptor interactions which can help
explain this interesting enhancement by Gal (1–15) of the antidepressant effects of 8-OH-DPAT [42].
This rather marked switch in the action of Gal (1–15) from inducing depression into antidepressant
activity when coactivated with the 5-HT1A receptor agonist may be related to the Gal (1–15)-induced
increases in the Bmax values of 5-HT1A high-affinity agonist binding sites. This takes place in the CA1
area and the dentate gyrus of the hippocampus, while a small reduction in the dorsal raphe develops
where the 5-HT1A autoreceptors are located [42]. These results were matched by a Gal (1–15)-induced
increase in the 5-HT1A mRNA levels in the hippocampus and a reduction of these levels in the dorsal
raphe. Such changes may help increase the signaling over the 5-HT1A receptor in the hippocampus
and reduce its signaling over the 5-HT1A autoreceptor.
Nevertheless, this increase in the density of hippocampal 5-HT1A receptors takes place in the
presence of a Gal (1–15)-induced reduction in the affinity of the high-affinity hippocampal 5-HT1A
agonist binding sites [42]. Thus, the increase in 5-HT1A-mediated 5-HT neurotransmission may mainly
develop with increased extracellular 5-HT levels, which may develop because the 5-HT autoreceptor
levels appear to become reduced. Further work is needed to understand the mechanism for the recently
discovered and highly interesting ability of Gal (1–15) to enhance the antidepressant actions of the
5-HT1A receptor agonist. It is clear, however, that 5-HT1AR can be in close proximity to both GalR1
and GalR2 using in situ PLA. Galanin appears to mainly target the GalR1–5-HT1A and GalR2–5-HT1A
heteroreceptor complexes, while Gal (1–15) mainly targets the GalR1–GalR2–5-HT1A complex.
It was proposed that in the GalR1–GalR2–5-HT1A heteroreceptor complex, the action of GalR2
is altered from enhancing Gi/o-mediated signaling of GalR1 in the GalR1–GalR2 heterodimer [66]
into enhancing 5-HT1A receptor signaling in the trimer complex by, inter alia, reducing 5-HT1AR
internalization from the plasma membrane [42]. In addition, GalR2 may also maintain its signaling over
Gq and PLC. In line with these results, it was found that Gal (1–15) enhanced the antidepressant effects
of the SSRI fluoxetine using the forced swim test [43] (Figure 2). In this case, however, extracellular
5-HT levels were elevated, likely increasing 5-HT signaling not only over the 5-HT1A receptor, but
also over a number of other 5-HT receptor subtypes known to produce antidepressant actions. As an
example, the 5-HT4R can be mentioned, a fast-onset antidepressant [26,29,68,69].
In the combined treatment with Gal (1–15) and fluoxetine, the modulation of the 5-HT1A agonist
binding sites in the dentate gyrus was also different from the modulation found with Gal (1–15). The
modulation by combined treatment with fluoxetine and Gal (1–15) produced an increased affinity of
the 5-HT1A agonist binding sites and a reduction of their Bmax values in the dentate gyrus [43], in
contrast to the reduced affinity and increased Bmax levels found in this region with Gal (1–15) [42].
However, the increase in 5-HT1A mRNA levels in the hippocampus was still obtained after the
combined treatment with Gal (1–15) and fluoxetine, as found after treatment with Gal (1–15) alone. It
was suggested based on these observations that Gal (1–15) given intranasally in depression may offer a
new treatment when combined with SSRIs or 5-HT1A receptor agonists to improve their antidepressant
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actions. The impact of the 5-HT1A receptors for the antidepressant actions was indicated from the
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As for galanin, which is a 29-amino acid neuropeptide (Gal (1–29)), it binds with high affinity to
GalR1, GalR2, or GalR3 receptors and shows a r duced affinity for the GalR1–GalR2 heteror ceptor
complex s [38,66] (Figure 2). It was proposed that galani can contribute to depression by inhibition
of firing in the dorsal raphe 5-HT nerve cells, sending projections into the telencep alon a d
diencephalon [44,70]. In the FSL rat model of depression, an incr ase in the galanin receptor bind ng
sites was found in the dorsal raphe, giving support to this view [71].
GalR1–5-HT1A heteroreceptor complexes were also demonstrated [37,46], a d later on, also
GalR2–5-HT1A heteroreceptor co plexes [42] (Figure 1). GalR2 is known to have antidepre sant
activity, in contrast to GalR1, which can contribute to depressive actions. This research illustrates
how galanin and its fragment Gal (1–15) can produce differential changes in mood from depressive to
antidepressant actions, being dependent on how the galanin receptor subtypes come together with the
5-HT1A receptors and probably other types of 5-HT receptor subtypes. The heteroreceptor complexes
formed from the GalR and 5-HT1A receptor subtypes with various stoichiometries will determine their
functions and role i major depression. The mol cular complexes formed are likely highly dynamic
and vary from one brain region to another o e. T e hippocampus appears to be a major target.
5. Isodimers and Heterodimers on the Receptor Interface, Especially of Serotonin
Receptor Homodimers
I the serot nin homo-, iso-, nd heterorec pt r complexes, the allosteric c mmunication between
the involved protomers takes place via the receptor interface. Thus, the interface interaction becomes a
key player and the understanding of the receptor interface necessary. Therefore, there is a significant
body of experimental and bioinformatic work that has focused on identifying key residues of the
receptor interface for serotonin homo- and heteroreceptor complex formation.
Based on biophysical and biochemical techniques, for instance, FRET (fluorescence resonance
energy transfer), BRET, coimmunoprecipitation, and mass spectrometry, several models of serotonin
receptor dimerization have been proposed. Some receptor domains have also been identified to be
involved in this phenomenon. The transmembrane (TM) domain disulphide bonds (Cys112 and
Cys145) play a key role in the homodimerization of 5-HT4R [72]. Instead, a negatively charged
motif at the C-terminal tail of 5-HT2AR drives the heterodimerization of 5-HT2AR with the D2R
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by means of the formation of noncovalent complexes [73]. This high-energy strength of double
arginine-phosphate electrostatic interaction interface mechanisms has also been found in the receptor
interface of the A2AR–D2R heteromer. It possesses a covalent-like stability, as demonstrated with
mass spectrometry and site-directed mutagenesis and BRET techniques [74,75]. On the other hand,
TM helix domains (especially the TM4 and TM5) are an important part of the receptor interface
in the 5-HT1A [76] and 5-HT2C [77] homoreceptor complexes. The participation of TM4 and
TM5 in the oligomer interface has also been demonstrated within other complexes such as the
serotonin 5-HT4 receptor homodimer [72], the chemokine CCR5 receptor homodimer [78], the α-factor
pheromone receptor (Ste2) homodimer [79], the corticotrophin-releasing hormone receptor/arginine
vasotocin receptor heterodimer [80], and the serotonin 5-HT2A/metabotropic glutamate receptor
2 heterodimer [81]. Furthermore, the transmembrane helixes (TM-5) and (TM-8) of 5-HT1A were
proposed to participate in the interface of the 5-HT1A–FGFR1 heteroreceptor complexes [6,40]. Overall,
today it is well-accepted and demonstrated that transmembrane helices participate in class A, B,
and C GPCR homo- and heterodimerization. The interaction interfaces are formed by lipid-exposed
surfaces within the transmembrane helical bundle of each individual protomer. Thus, alterations in
the receptor hydrophobic core, particularly residues containing the ligand-binding site, predictably
affect the receptor conformation and oligomerization.
Also based on mathematical and bioinformatic approaches, it is possible to understand the
receptor–receptor interface interaction. For instance, it was proposed that structurally homologous
amino acid residues can play a role in the receptor interface [62]. Through mathematical models
and bioinformatic analysis, it became possible to demonstrate that known heterodimers, but not
nonheterodimers, contained a number of protriplets in a putative receptor interface [62,82]. These
protriplets appeared to be essential for the coming together of the two receptors into a heterodimer.
The protriplet puzzle theory was introduced in 2010, but contratriplets may also exist [62,83].
Nonintersecting sets of protriplets and contratriplets were obtained from various lists of receptor
pairs [82]. Any protriplet is shown to be a homology in at least one heterodimer, but is not found as
a homology in any nonheterodimer, and promotes heteromerization. The protriplets theory makes
sense because hot spots in the receptor interface are often protected by residues that are not relevant
for binding, but the role of which is to isolate the hot spots from the surrounding solvent [82,84].
It should be noticed that protriplet amino acid homologies have been identified in all the serotonin
iso- and heteroreceptor complexes in the current article (Table 1). In the 5-HT1A–FGFR1 heteroreceptor
complex, the TLG (Thr–Leu–Gly) and AAR (Ala–Ala–Arg) protriplets were demonstrated [6,34]. In the
5-HT1A–5-HT2A isoreceptor complex, the LLG (Leu–Leu–Gly) and QNA (Gln–Asn–Ala) protriplets
were found [34]. In the 5-HT1A–GalR1 and 5-HT1A–GalR2 heteroreceptor complex, protriplets
LLG, LAR (Leu–Ala–Arg), and RNA (Arg–Asn–Ala) were identified, which was true also for the
GalR1–GalR2 isoreceptor complex [34,37].
The findings that the different types of GalR isoreceptor and heteroreceptor complexes use
the same protriplets, leading to competition for the same receptor interface, can help explain the
alteration in the allosteric receptor–receptor interactions found in the putative GalR1–GalR2–5-HT1A
heteroreceptor complex. As postulated, it may be that in the trimeric complex, the GalR2 signaling
dominates, including an enhancement of 5-HT1A signaling through a positive allosteric mechanism.
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Table 1. Demonstration of protriplet amino acid homologies in 5-HT1AR–FGFR1, 5-HT1AR–5-HT2AR, and GalR1–GalR2 heterodimers.
Galanin Set Serotonin Set 2010 [37] 2012 [6] 2017 [34]
VLA NGS GAF LIF LAA SLA VLV DVL LAR SNS AAR LLG TLG QNA RNA
5-HT1AR + + + + + + + + + + + +
FGFR1 + + + + + + + + +
GalR1 + + + + + + + + + +
GalR2 + + + + + +
5-HT2AR + + + + +
Some protriplets were reported in in previous works by Borroto-Escuela et al. [6,34,37]. Others were found in lists (sets) of receptor pairs mainly involving galanin or serotonin receptors.
The protriplets only exist in heterodimers and are not found in nonheterodimers. At least the majority of these protriplet homologies appear to be part of the receptor interface. (+)it refer
to the presence of the protriplet in the protomer.
Molecules 2018, 23, 1341 10 of 16
6. Concluding Remarks
It appears clear that multiple 5-HT1A heteroreceptor complexes exist in the hippocampus,
modulating its GABA and glutamate synapses. Through this modulation, these heteroreceptor
complexes change the activity of the hippocampal networks and thus their outputs to mood-regulating
limbic areas. Their modulation of these networks may mediate the antidepressant actions produced
by 5-HT1A receptor activation. It is not known which of the 5-HT1A heteroreceptor complexes
plays a leading role in reducing depression: 5-HT1A–FGFR1, 5-HT1A–5-HT2A, GalR–5-HT1A, or
GalR1–GalR2–5-HT1A heteroreceptor complexes. It remains to establish if these different 5-HT1A
complexes can modulate the same or different glutamate and GABA synapses in the hippocampus.
Their architecture in terms of their individual distribution in the CA1–CA4 regions and the dentate
gyrus and their layers is still relatively unknown and should be determined. They mainly have a
postjunctional location. As an example, it is shown in Figure 3 that the 5-HTA–5-HT2A isoreceptor
complexes are mainly located in the pyramidal cell layer of CA1–CA3 areas, with few complexes in
other regions of the dorsal hippocampus. It will be of high interest to determine if some of them are in
balance with each other, which can be altered by 5-HT and other transmitters. Future work should
determine which complex is the most vulnerable in depression development. Restoring its activity
may be of special value to reducing depression.
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Figure 3. Illustration of the distribution pattern of 5-HT1A–FGFR1 heteroreceptor and 5-HT1A–5-HT2A
isoreceptor complexes visualized with PLA in the rat dorsal hippocampus. The 5-HT1A–FGFR1
heteroreceptor complexes, in red, have a more widespread distribution, mainly located within the
pyramidal cell layer of the CA1–CA4 and in the plexiform cell layer of the dentate gyrus. However, they
exist in low densities in the stratum oriens and radiatum of the C 1–CA4 regions and the subgranular
layer. Instead, the 5-HT1A–5-HT2A isoreceptor complexes, shown in yellow, are concentrated to
the pyr midal c ll layer of the CA1–CA3 regions, with some located in the subgranular layer of the
dentate gyrus.
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The following abbreviations are used in this manuscript:
5-HT1A serotonin 5-HT1A receptor subtype
5-HT2A serotonin 5-HT2A receptor subtype
CNS central nervous system
FGFR1 fibroblast growth factor receptor 1 subtype
FSL Flinders sensitive line rats
FST forced swim test
Gal (1–15) galanin N-terminal fragment peptide (1–15)
Gal (1–29) galanin peptide (1–29)
GIRK G protein-coupled inwardly rectifying potassium channels
GPCR G protein-coupled receptor
i.c.v. intracerebroventricular
RTK receptor tyrosine kinase
SD Sprague Dawley rats
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